The combination includes: a cellular adherent component (HS5 - BM derived stromal cells), soluble factors such as CpG + IL2 and the addition of human serum, CLL plasma and erythrocyte fraction. This evidence concerns the gene IL2 and B-cell chronic lymphocytic leukemia.